Gastrointestinal Therapeutics Market is anticipated to reach USD 65.1 billion by 2025. The market is anticipated to rise at a healthy growth rate in the years to come. Gastrointestinal disorders are medical situations associated with the digestive system that disturb the small & large intestine, colon, and rectum. The syndromes mostly comprise peptic ulcer diseases, irritable bowel syndrome and constipation, categorized by several symptoms and signs such as bloating, pain, diarrhea, vomiting, and nausea. Gastrointestinal therapeutics comprises medications, which are commercially accessible in the market namely Afinitor, Aciphex, Akynzeo, Prilosec and Dificid.
In
addition, the factors that propel the growth of market comprise the growing
healthcare spending, increasing geriatric population, rising prevalence of
gastrointestinal disease due to additional numbers of clinical trials, unhealthy
dietary habits. On the other hand, the high competition among several key
players to lead the market may ultimately rule the price attrition, and hamper
the growth of market. However, these Gastro intestinal therapeutics have side
effects, such as they have a low diagnosis rates, and stern rules for the
approval of drugs. These factors will limit the growth of market in the years
to come. The market is anticipated to grow at a significant CAGR of 6.6% in the
upcoming period as the scope, product types and its applications are increasing
across the globe.
Request Sample Copy of This Market Research @
https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market/request-sample
Gastrointestinal
Therapeutics industry may be explored by type, Route Administration,
applications, Distribution Channel and geography. The market may be explored by
type as Branded, (Antacids, Enzyme Replacement Therapies, Amino salicylates,
Proton Pump Inhibitors, H2 Antagonists, Laxatives, Antiemetics, Biologics,
Antidiarrheals, others), Generics. Branded gastrointestinal drugs dominated the
market in 2016. However, it is anticipated to observe a decline in CAGR during
the upcoming period due to saturation of generic medicines in the market.
Gastrointestinal
Therapeutics Market may be explored by Route Administration as Intravenous,
Oral, and Others. “Intravenous” segment dominated the route administration in
the industry in 2016. Gastrointestinal Therapeutics industry may be explored by
applications as GERD, Ulcerative Colitis, Crohn’s Disease, and others. “Others”
segment dominated the market in 2016. This “others” segment may comprise
chronic idiopathic constipation, irritable bowel syndrome opioid-induced
constipation, diarrhea, nausea, recurrent gastrointestinal infections,
gastrointestinal stromal tumor, and pancreatic insufficiency.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market
Gastrointestinal
Therapeutics Market may be explored by Distribution Channel as Online
Pharmacies, Hospital Pharmacies, and Retail Pharmacies. The Online pharmacies
segment dominated the Gastrointestinal Therapeutics industry in 2017. Moreover,
increasing occurrence of chronic diseases. In addition, growing incidence of
chronic diseases has caused in an extensive gap in the source of and demand for
main drugs. The factors are anticipated to present remunerative development
projections for online pharmacies throughout the upcoming period.
North
America accounted for the major share of the global Gastrointestinal
Therapeutics Market Size Analysis in 2016 and will continue to rule the roost
in the forecast period. The market for Gastrointestinal Therapeutics in North
America, especially in the U.S., is the most lucrative one and gaining robust
traction from numerous features such as changing lifestyle, resultant in grater
occurrence of gastrointestinal diseases will upsurge the gastrointestinal
therapeutics in North America region in the years to come. North America
followed by Asia-Pacific region.
Some
of the key players that fuel the growth of the gastrointestinal therapeutics
industry include Johnson & Johnson, Abbott Laboratories, AbbVie Inc., Salix
Pharmaceuticals, Pfizer Inc, AstraZeneca, Takeda Pharmaceutical Company
Limited, Astellas Pharma US, Inc., ALLERGAN, and GlaxoSmithKline Plc. The
leading companies are taking up partnerships, mergers and acquisitions, and
joint ventures in order to boost the inorganic growth of the industry.
Comments
Post a Comment